2 recruiting, 2 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Terminated 2 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow ITB-Med LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients TCD601 - ALS | Phase 1 | Terminated | ITB-Med LLC | 7 | 2024-04-16 | 2026-07-17 |
| Delayed Tolerance Through Mixed Chimerism Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine - Kidney Failure, Kidney Transplant; Complications | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 20 | 2023-10-01 | 2026-09-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Cholangitis, Sclerosing (1) · Disease (1) · End Stage Liver Disease (1) · Hepatitis, Autoimmune (1) · Liver Cirrhosis (1) · Renal Insufficiency (1) · Sickle Cell Trait (1)
siplizumab (4) · Cyclophosphamide (2) · Rituximab (2) · Biosimilar Pharmaceuticals (1) · Bone Marrow Transplantation (1) · Exchange Transfusion, Whole Blood (1) · Mesna (1) · Sirolimus (1) · Whole-Body Irradiation (1) · fludarabine (1)
United States (3) · Sweden (1)
Elizabeth Verna, MD (1) · Fredrik Julin (1) · Markus Y Mapara, MD, PhD (1) · Tatsuo Kawai (1)